Welcome to our dedicated page for Innate Pharma S.A. ADS news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma S.A. ADS stock.
Innate Pharma S.A. (Symbol: IPHA) is a clinical-stage biotechnology company at the forefront of cancer treatment innovation. Specializing in immuno-oncology, Innate Pharma develops first-in-class therapeutic antibodies designed to harness the innate immune system. This pioneering approach helps the body's natural defenses recognize and combat cancer cells more effectively.
The company's diverse pipeline includes four clinical-stage antibodies along with several preclinical candidates. Key products under development include lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401, and IPH6501. These therapies aim to address a wide range of cancer types, particularly those with high unmet medical needs.
Innate Pharma has made significant strides in the discovery and development of checkpoint inhibitors, leveraging its deep understanding of natural killer cell biology. This expertise has led to strategic partnerships with renowned biopharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi.
The company’s revenue streams primarily come from research collaborations, licensing agreements, and milestone payments from its pharmaceutical partners. Innate Pharma's proprietary platform, ANKET (Antibody-based NK cell Engager Therapeutics), forms the backbone of its innovative therapeutic strategies.
With a commitment to advancing cancer treatment, Innate Pharma continues to make significant progress in clinical trials and research, aiming to bring transformative therapies to patients worldwide.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) is set to present preliminary results from the TELLOMAK Phase 2 trial evaluating lacutamab for advanced Sézary syndrome at the ASH Annual Meeting, December 10-13, 2022, in New Orleans. Highlights include an oral presentation by CSO Eric Vivier on the ANKET™ platform and two poster presentations by partner Sanofi on SAR'579/IPH6101 and SAR'514/IPH6401. Lacutamab, a first-in-class anti-KIR3DL2 antibody, has received EMA PRIME designation and FDA Fast Track status for treatment in Sézary syndrome patients.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) has announced that its senior management team will participate in two upcoming investor conferences. The Stifel 2022 Healthcare Conference is scheduled for November 15-16, 2022, in New York, while the Evercore ISI HealthConX Conference will take place from November 29 to December 1, 2022, virtually. Innate Pharma focuses on oncology, developing therapeutic antibodies that utilize the immune system to enhance cancer treatment outcomes. It has a robust pipeline and strategic collaborations with major biopharmaceutical companies.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) has released its 2023 financial calendar, scheduling key financial reports throughout the year. Important dates include:
- March 23, 2023: Publication of 2022 financial statements
- May 10, 2023: 1Q2023 revenue announcement
- September 14, 2023: Half-year financial statements
- November 14, 2023: 3Q2023 revenue release
All reports will be made public before market open CET. For more details about the company and its activities, visit the website.
Innate Pharma has presented preliminary data at the EORTC CLTG annual meeting, demonstrating promising clinical responses from its anti-KIR3DL2 antibody, lacutamab, in patients with mycosis fungoides (MF) who have undergone previous systemic therapies. The Phase 2 TELLOMAK trial revealed a global objective response rate of 28.6% in KIR3DL2-expressing patients, with a favorable safety profile. The company anticipates sharing final data from this trial in 2023, alongside ongoing studies for other lymphomas.
Innate Pharma reported consolidated financial results for the first half of 2022, showcasing a net income of €6.3 million compared to a net loss of €23.7 million in the same period last year. Revenue surged to €45.6 million, primarily driven by milestone payments and collaborations with AstraZeneca and Sanofi. Notably, the company advanced the anti-CD39 monoclonal antibody IPH5201 into Phase 2 trials and received a €3 million milestone for IPH6401/sar514. With a strong cash position of €158.2 million, Innate is well-funded through H2 2024.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) announced a conference call scheduled for September 15, 2022, at 2 p.m. CEST to discuss its business progress in the first half of 2022. The call will feature CEO Mondher Mahjoubi and other executives. A live webcast will be available, with a replay accessible on the company’s website for 90 days post-event. Innate Pharma focuses on clinical-stage oncology therapies, leveraging its expertise in immune system targeting to develop innovative antibody treatments. Visit www.innate-pharma.com for more details.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) announced key presentations at the ESMO Annual Meeting 2022 in Paris from September 9-13. Highlights include:
- Poster Presentation: Ongoing Phase 1b trial of lacutamab for peripheral T-cell lymphoma.
- Oral Presentation: ANKET platform by Eric Vivier focusing on multispecific antibodies for NK cell activation.
- Mini Oral Presentation: AstraZeneca's Phase 2 NeoCOAST study on durvalumab in early-stage NSCLC.
Lacutamab targets KIR3DL2 expressed in certain aggressive lymphomas, showcasing Innate's innovative approaches in oncology.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced participation in investor conferences, including Citi's 17th Annual BioPharma Conference on September 7-8, 2022, and H.C. Wainwright's 24th Annual Global Investment Conference from September 12-14, 2022. The company, focused on oncology, is advancing several first-in-class therapeutic antibodies aimed at enhancing cancer treatment outcomes. With a strong pipeline and partnerships with major biopharmaceutical leaders, Innate is committed to improving patient care in high unmet medical need areas.
Innate Pharma has released its total number of shares outstanding and voting rights as of August 1, 2022. The company has 79,893,019 ordinary shares and 6,514 preferred shares from 2016 and 7,581 from 2017. The total theoretical voting rights stand at 80,650,859, with exercisable voting rights at 80,632,284. This disclosure is in compliance with French regulations to ensure transparency for shareholders.
Innate Pharma announced that the INTERLINK-1 Phase 3 study, sponsored by AstraZeneca, did not meet the efficacy threshold during an interim analysis and will be discontinued. The trial evaluated monalizumab with cetuximab against cetuximab alone for patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Despite this setback, Innate remains optimistic about monalizumab's potential in lung cancer and continues to focus on ongoing studies like PACIFIC-9 and NeoCOAST-2. AstraZeneca will share data from the trial in the future.
FAQ
What is the current stock price of Innate Pharma S.A. ADS (IPHA)?
What is the market cap of Innate Pharma S.A. ADS (IPHA)?
What does Innate Pharma S.A. specialize in?
What are some of Innate Pharma's key products?
How does Innate Pharma generate revenue?
Who are some of Innate Pharma's notable partners?
What is ANKET?
What is the focus of Innate Pharma’s current projects?
What stage is Innate Pharma in?
What makes Innate Pharma's approach unique?
What is immuno-oncology?
How does Innate Pharma contribute to cancer research?
